bioRxivImmunologyPreprint
The abscopal effect of Combination IRE with anti-PD-1 achieves local ablation and systemic control of PDAC
Qizhen CaoiD, Zhenzhen XuniD, Yitao TangiD, Jiakai Hou, Boping JingiD, Ping Pan, Jing Zhang, Shiaw-Yih Lin, Sanjay Gupta, Jared K. BurksiD, Huanmin Wang, James P. LongiD, Han LiangiD, Weiyi PengiD, Chun LiiD
Abstract
Irreversible electroporation (IRE) has shown promise for treating pancreatic ductal adenocarcinoma (PDAC), but whether IRE can induce an abscopal effect is not established. We demonstrated that the combination of IRE and anti-PD-1 antibody could trigger robust abscopal effects in preclinical models of metastatic PDAC. Data from multiple in vivo models, RNA-seq, scRNA-seq, and spatial immunofluorescence provide compelling evidence that IRE induced mitochondrial dysfunction and cellular stress, which triggered activation of the cGAS-STING pathway and subsequent systemic antitumor effects. IRE also led to inflammatory response characterized by tumor infiltration of myeloid cells and their polarization toward M1 state, turning immunologically "cold" tumors into "hot" tumors. Moreover, the presence of T cell/B cell clusters in tumors from mice treated with IRE plus PD-1 and the lack of antitumor efficacy in B cell knockout mice bearing orthotopic murine PDAC tumors indicate that B cells play an important role in IRE-mediated systemic antitumor immunity. SignificanceThis study shows that IRE plus a checkpoint inhibitor represents a promising therapeutic strategy for PDAC and supports advancing this treatment toward clinical translation. Our data also support potential combination strategies with immunomodulatory agents that can recruit and reprogram B cells to support T cell activation and cytotoxic effector functions.
- organism: mouse
- assay: scRNA-seq
- assay: bulk RNA-seq
- assay: spatial transcriptomics
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model.
J. S. S. Narayanan, T. Hayashi, … R. R. White·bioRxiv·Oct 4, 2022
- Novel combination of irreversible electroporation and allogenic chimeric antigen receptor (CAR) T-cell therapy synergizes therapeutic outcomes in a preclinical human pancreatic cancer mouse model
Edward J. Jacobs, Julio P. Arroyo, … Rafael V. Davalos·ResearchPeer-reviewed·Jan 1, 2026
- Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer
K. K. Mahadevan, A. M. Dyevoich, … R. Kalluri·bioRxiv·Mar 5, 2023
- IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer
Akash R. Boda, Irfan N. Bandey, … Manisha Singh·bioRxiv·Feb 23, 2025
- Dual blockade of IL-6 and CTLA-4 regresses pancreatic tumors in a CD4+ T cell-dependent manner.
M. B. Ware, C. McQuinn, … G. B. Lesinski·bioRxiv·Feb 7, 2020
- Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer
Lincoln N. Strickland, MacKenzie V. Demmel, … Jennifer M. Bailey·bioRxiv·Jul 1, 2026